Helen Tayton-Martin

CEO

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Evaxion A/S (EVAX)
CEO

Source not stated

Current
Adaptimmune Therapeutics PLC (ADAPY)
Proxy statement

Current
Adaptimmune Therapeutics PLC (ADAPY)
Proxy statement

Start not stated–2025-03-31

Recorded roles and earnings-call appearances connecting this person to public companies.

EVAX

Current role

CEO

1 call Latest call 2026-03-31

ADAPY

Current role

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2023	Adaptimmune Therapeutics PLC (ADAPY)	Chief Business & Strategy Officer	$449,004	—	—	$505,950	$191,949	$36,451	$1,183,352
2022	Adaptimmune Therapeutics PLC (ADAPY)	Chief Business & Strategy Officer	$449,004	—	—	$814,474	$60,615	$36,201	$1,360,293
2021	Adaptimmune Therapeutics PLC (ADAPY)	Chief Business & Strategy Officer	$438,052	—	—	$1,069,101	$187,267	$44,232	$1,738,652
2020	Adaptimmune Therapeutics PLC (ADAPY)	Chief Business Officer	$450,881	—	—	$857,661	$223,186	$23,321	$1,555,050
2019	Adaptimmune Therapeutics PLC (ADAPY)	Chief Business Officer	$432,059	—	—	$766,900	$136,099	$30,219	$1,365,277

Earnings-call appearances and filed executive appointments or departures, newest first.